Roche to buy intestinal disease drug from Roivant and Pfizer for more than $7 billion
Roche to buy intestinal disease drug from Roivant and Pfizer for more than $7 billion
Updated October 23, 2023 at 6:55 a.m. ET
rock Holding has agreed to buy the developer of a treatment for intestinal diseases from Roivant Sciencesa company created by the Republican presidential candidate Vivek RamaswamyAnd Pfizer in a deal worth more than $7 billion.
The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings and make a near-term milestone payment of $150 million. Roche said the deal gives it the right to commercialize Telavant’s drug candidate RVT-3101, which has shown promise in treating inflammatory bowel disease and may have potential in other indications, including: United States and Japan.
Copyright ©2023 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Wj